Jacques Besnainou

A corporate mobility platform that brings operational and financial efficiency to day-to-day processes. For mobility and logistics managers who need to reach their transportation and environmental goals, Netlift is a corporate mobility platform that brings operational and financial efficiency to day-to-day processes. Unlike other logistics softwares,Netlift is a central hub for optimizing transportation activities, organizing employee commute and simplifying parking management.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

A corporate mobility platform that brings operational and financial efficiency to day-to-day processes. For mobility and logistics managers who need to reach their transportation and environmental goals, Netlift is a corporate mobility platform that brings operational and financial efficiency to day-to-day processes. Unlike other logistics softwares,Netlift is a central hub for optimizing transportation activities, organizing employee commute and simplifying parking management.

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Established in 2002, General Fusion is a global leader in the race to commercialize clean fusion energy. We are pursuing a uniquely practical approach, Magnetized Target Fusion, and aim to provide zero-carbon fusion power to the grid in the early to mid-2030s. Today at our state-of-the-art labs in Richmond, BC, we’re operating a groundbreaking fusion demonstration machine called Lawson Machine 26 (LM26), designed to achieve transformational technical milestones and accelerate General Fusion’s technology to commercialization. Our path to market is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.

BioFortis is a leading provider of precision medicine software solutions. Its flagship product, Labmatrix, is a web-based database application that addresses the needs in clinical trial sample and consent tracking, study subject and biospecimen management, and collaborative clinical & translational research programs. With enterprise-grade capabilities for importing, integrating, and access controlling multiple eClinical and bioresearch data collections in a tightly-linked and regulatory-compliant manner, Labmatrix further empowers its users to easily ask sophisticated questions and generate scientific insights/reports, thus breaking down the technical barriers to big & complex data access and exploration.